What ChondroFiller actually is

ChondroFiller™ is none of the things patients most commonly expect from a hip injection. It is not a corticosteroid, not a lubricating viscosupplement, and not a permanent joint filler. It is also not a cell-based therapy — no donor cells or lab-grown tissue are involved. What it is, precisely, is a CE-marked Class III medical device: an acellular injectable Type I collagen hydrogel manufactured by Meidrix Biomedicals GmbH in Germany.

Delivered as a liquid into a focal hip cartilage defect under ultrasound guidance, ChondroFiller™ polymerises into a porous three-dimensional scaffold within approximately 3–5 minutes. That scaffold then works through a process called acellular matrix-induced chondrogenesis — in plain terms, the collagen framework acts as a ready-made template that the patient's own progenitor cells, drawn from the synovium and subchondral bone, can migrate into and populate. The repair comes from the patient's own biology, not from anything introduced with the injection.

Over 12–24 months, the scaffold gradually resorbs as the body replaces it with repair tissue. Laboratory evidence published in 2025 from an ex vivo human osteochondral study recorded a 2.4-fold increase in DNA content within the scaffold by day 14 — confirming that cell recruitment does occur at a biologically meaningful scale.

The collagen is murine-derived, which is relevant for patients with relevant allergy histories, though published clinical evaluations have not reported adverse events attributable to the material.

Which hip patients are suitable — and which are not

Deciding whether ChondroFiller™ is appropriate starts with the state of the hip joint, not the intensity of the pain — a distinction that matters more than most patients expect.

The clearest positive profile is a younger, active individual with an isolated, full-thickness (Grade III or IV) focal defect on the acetabular surface, with healthy cartilage at the margins and early-stage hip disease. Cam-type femoroacetabular impingement (FAI) is the prototypical route to this picture: the abnormal bony shape of the femoral head produces anterosuperior acetabular lesions that, if left unaddressed, can progress steadily towards osteoarthritis. Treating those lesions at the focal stage — before widespread joint deterioration — is precisely where this type of scaffold intervention is positioned.

The published hip cohort (Jerosch group, JHPS 2021) makes the boundary explicit. Patients with pre-existing Tönnis Grade 2–3 osteoarthritis had poor outcomes, whilst 17 of 21 patients without established OA achieved good or excellent results at 3–5 years. The Tönnis grading threshold is therefore clinically meaningful, not administrative.

This also explains why pain level alone is a poor guide to candidacy. A patient with severe symptoms arising from a single contained defect on an otherwise healthy joint may be well suited; someone with moderate pain spread across a diffusively worn joint is not. For diffuse hip OA requiring cushioning rather than focal repair, a different intervention — such as Arthrosamid — addresses a different problem at a later disease stage.

A consultant assessment, including imaging, is needed to determine which category applies to any individual.

What the hip evidence shows

The Jerosch group cohort described in the previous section — 26 patients with FAI and acetabular defects greater than 2 cm², followed for 3–5 years — remains the primary published hip-specific dataset. Beyond the candidacy threshold it establishes, the study contains two details worth noting: only 21 of the 26 original patients were evaluable at final follow-up, and 2 of those 21 required total hip replacement, meaning the 81% good-or-excellent rate is drawn from a subset, not the full cohort.

In aggregate published hip data, the mean Harris Hip Score improvement reported is approximately +33 points. The Harris Hip Score is a 100-point clinician-assessed scale measuring pain, function, and range of motion; a shift of this magnitude crosses the recognised threshold for a clinically meaningful change in daily life. MRI MOCART scores of 70–87 have been recorded at follow-up; MOCART (Maximum Outcome Criteria for Articular Cartilage Repair) is a standardised imaging grading system where higher scores indicate more complete, structurally integrated cartilage-like tissue fill.

Over 19,000 ChondroFiller® procedures have been performed globally across multiple joints. That cumulative volume provides a safety and tolerability context — no meaningful adverse-event signal has emerged — but it is not the same as outcome data and should not be read as such.

The honest summary of the evidence position is this: published hip data are promising but drawn from relatively small cohorts. No large randomised controlled trial in the hip joint has been completed, and no head-to-head comparison with microfracture in the hip has been published. These are gaps the field has yet to close, not grounds for dismissing what the existing studies show.

How the injection appointment works

The appointment at Lincolnshire Hip is an outpatient visit — no general anaesthetic, no theatre admission, no surgical incisions.

One thing worth stating clearly at the outset: the published hip studies referenced in the previous section used arthroscopic delivery under general anaesthetic. That is a meaningfully different clinical setting from the image-guided injection pathway offered here. The research informs patient selection and the treatment rationale; the delivery route itself is distinct.

At the clinic, ChondroFiller™ is placed under ultrasound guidance during a standard outpatient appointment. Under real-time imaging, the clinician guides a fine needle to the focal acetabular defect and injects the collagen as a liquid directly into the lesion. Once inside the joint, it sets into a sponge-like, porous structure within approximately three to five minutes — no surgical exposure required. Nothing is added to the product beforehand; it arrives ready to use, and the patient's own progenitor cells do the repair work after placement.

The full procedure is completed within a single clinic visit. Because the scaffold remains mechanically vulnerable before it integrates with surrounding tissue, some weight-bearing restriction is advisable in the early weeks following the injection — the exact programme will depend on individual circumstances and is confirmed at assessment.

Recovery and what to expect in the months after

A 2024 biomechanical study is the reason weight-bearing restriction after the procedure is a clinical requirement rather than an optional precaution. Under repeated cyclic loading, the freshly placed scaffold demonstrated initial mechanical instability — sufficient that the adjacent cartilage may not be adequately protected if full weight is applied too early. The early restriction window allows the collagen matrix to stabilise in place and the patient's own progenitor cells to begin migrating into the structure before it is exposed to the full demands of normal joint loading.

Improvement after treatment is gradual rather than immediate. The scaffold does not repair cartilage on the day of the appointment; it establishes the conditions for the body's endogenous repair processes to take hold, and that biological sequence unfolds across months. Structural tissue integration is typically assessed by MRI at around 12 months, which can confirm how well the treated area has consolidated. Clinical improvement in pain and hip function tends to follow a similar timeline rather than leading it.

Patients should expect protected weight-bearing in the early post-procedure weeks, with return to higher-impact activity timed around individual joint response — confirmed at follow-up rather than fixed in advance. The individuals who tend to do best going into this treatment are those who understand from the outset that it is a slow biological process: they do not spend the first few months looking for a recovery that the science cannot yet deliver.

Access, cost, and next steps in Lincolnshire

ChondroFiller™ is not available on the NHS; private UK pricing ranges from approximately £3,000 to £9,800 depending on the care package — a range that reflects defect complexity, imaging, and follow-up rather than a single fixed procedure cost. A clinician can give a specific rather than indicative figure at assessment.

For patients in Lincolnshire and the wider East Midlands, Professor Paul Lee offers ChondroFiller assessment and treatment at clinics in Grantham and Sleaford — no GP referral is required to book. Before attending, a published online suitability tool at Lincolnshire Hip allows patients to evaluate their candidacy across physical, biological, and timing dimensions; for those still weighing options, it is a practical low-friction starting point that does not require a clinic visit.

On regulatory standing: ChondroFiller carries CE-mark Class III medical device status, but has not, at the time of writing, received a specific NICE technology appraisal in the UK. That question is worth raising directly at consultation, where the current commissioning context can be discussed clearly.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment. The patients best placed to benefit from this pathway are those who arrive early — with a contained focal defect, healthy surrounding tissue, and a clear understanding that cartilage repair is a biological process measured in months, not days.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Hip Chondral Defects: Arthroscopic Treatment With the Needle and Curette Technique and ChondroFiller. (2021). https://doi.org/10.1016/j.eats.2021.03.011 https://doi.org/10.1016/j.eats.2021.03.011
3. [3] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
4. [4] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759